Z-2105-2021 Class II Terminated

Recalled by Cell Marque Corporation — Rocklin, CA

FDA device recall Z-2105-2021 was initiated by Cell Marque Corporation on May 27, 2021 and is designated Class II. Reason for recall: Product distributed for use as an In-vitro Diagnostics without FDA clearance The recall status is terminated (terminated Apr 5, 2024). Affected quantity: 41 kits.

Recall details

Product Type
Devices
Report Date
Jul 28, 2021
Initiation Date
May 27, 2021
Termination Date
Apr 5, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
41 kits

Product description

Cell Marque, RabMAb,CD17, c-kit (YR145) Rabbit Monoclonal Primary Antibody, REF: 117R-18, IVD, CE, GTIN: 00841683123798

Reason for recall

Product distributed for use as an In-vitro Diagnostics without FDA clearance

Distribution pattern

US: AL, AR, AZ, CA, FL, HI, ID, IL, KY, MN, MT, NC, NH, NY, PA, SC, VA, WI OUS: N/A

Code information

Lot Numbers: 0000058081/ Exp: 31 Dec 2021, 0000072580/ Exp: 30 Sep 2021, 0000090505/ Exp: 30 Sep 2022, 0000121052/ Exp: 31 May 2023

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-2105-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-2105-2021. Report a data issue: hello@regdatalab.com.